The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

30 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Full Sequence Amino Acid Scanning of¿-Defensin RTD-1 Yields a Potent Anthrax Lethal Factor Protease Inhibitor.EBI
State University Of New York
Probing the S2' Subsite of the Anthrax Toxin Lethal Factor Using Novel N-Alkylated Hydroxamates.EBI
University Of Minnesota
Exploring the influence of the protein environment on metal-binding pharmacophores.EBI
University Of California
Small molecule inhibitors of anthrax lethal factor toxin.EBI
Microbiotix
D-proline-based peptidomimetic inhibitors of anthrax lethal factor.EBI
TBA
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI
Panthera Biopharma
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.EBI
Microbiotix
Amiodarone and bepridil inhibit anthrax toxin entry into host cells.EBI
University Of California
Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.EBI
Purdue University
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI
Microbiotix
Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.EBI
Panthera Biopharma
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.EBI
University Of California
Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.EBI
Panthera Biopharma
In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.EBI
National Institute Of Allergy And Infectious Diseases
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.EBI
Institute For Medical Research
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.EBI
Institute For Medical Research
Inhibitors of anthrax lethal factor.EBI
Purdue University
In-cell production of a genetically-encoded library based on the ?-defensin RTD-1 using a bacterial expression system.EBI
University Of Southern California
Small molecule inhibitors of anthrax edema factor.EBI
Hawaii Biotech
In silico binding analysis and SAR elucidations of newly designed benzopyrazine analogs as potent inhibitors of thymidine phosphorylase.BDB
Universiti Teknologi Mara (Uitm)
D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.BDB
Case Western Reserve University
Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism.BDB
University Of North Carolina At Chapel Hill
Discovery of a New Class of Potent, Selective, and Orally Bioavailable CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases.BDB
Merck Serono
Arginine binding motifs: design and synthesis of galactose-derived arginine tweezers as galectin-3 inhibitors.BDB
Lund University
Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-beta Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-beta Receptor Type I Inhibitor as Antitumor Agent.BDB
Eli Lilly